Emmett V Schmidt

List of Publications by Year
in descending order

38 papers	4,980 citations	201674 27 h-index	315739 38 g-index
38 all docs	38 docs citations	38 times ranked	6403 citing authors

#	Article	IF	Citations
1	The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncology, 2021, 17, 637-648.	2.4	42
2	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncology, The, 2021, 22, 946-958.	10.7	100
3	Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development. Contemporary Clinical Trials, 2021, 106, 106434.	1.8	7
4	Independent drug action and its statistical implications for development of combination therapies. Contemporary Clinical Trials, 2020, 98, 106126.	1.8	9
5	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology, 2020, 38, 2981-2992.	1.6	364
6	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 711-718.	10.7	381
7	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). Journal of Clinical Oncology, 2018, 36, 3223-3230.	1.6	267
8	Cyclin D1 Enhances the Response to Estrogen and Progesterone by Regulating Progesterone Receptor Expression. Molecular and Cellular Biology, 2010, 30, 3111-3125.	2.3	31
9	Genome-wide analysis of YY2 versus YY1 target genes. Nucleic Acids Research, 2010, 38, 4011-4026.	14.5	49
10	Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle, 2009, 8, 1344-1351.	2.6	46
11	c-myc Repression of TSC2 Contributes to Control of Translation Initiation and Myc-Induced Transformation. Cancer Research, 2007, 67, 11209-11217.	0.9	50
12	Cell-based models of sustained, interferon-sensitive hepatitis C virus genotype 1 replication. Journal of Virological Methods, 2006, 132, 195-203.	2.1	12
13	Identification of Cyclin D1â€“ and Estrogen-Regulated Genes Contributing to Breast Carcinogenesis and Progression. Cancer Research, 2006, 66, 11649-11658.	0.9	68
14	hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation. Molecular and Cellular Biology, 2005, 25, 6436-6453.	2.3	111
15	Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology, 2005, 128, 1034-1041.	1.3	141
16	Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth. Journal of Biological Chemistry, 2004, 279, 3327-3339.	3.4	62
17	The role of c-myc in regulation of translation initiation. Oncogene, 2004, 23, 3217-3221.	5.9	143
18	The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer. American Journal of Pathology, 2004, 164, 1031-1038.	3.8	44

#	Article	IF	Citations
19	Forced expression of cyclin D1 does not compensate for Id2 deficiency in the mammary gland. FEBS Letters, 2003, 551, 123-127.	2.8	7
20	Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System. Journal of Virology, 2002, 76, 8505-8517.	3.4	187
21	Genes Involved in Breast Cancer Progression. American Journal of Pathology, 2002, 161, 1973-1977.	3.8	3
22	Activation of different Wnt/Î²-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene, 2002, 21, 5548-5556.	5.9	113
23	IKKÎ± Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development. Cell, 2001, 107, 763-775.	28.9	459
24	In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53. Transgenic Research, 2001, 10, 471-478.	2.4	12
25	Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. Journal of Clinical Investigation, 2001, 107, 1093-1102.	8.2	208
26	The Oncoprotein Kinase Chaperone CDC37 Functions as an Oncogene in Mice and Collaborates with Both c- myc and Cyclin D1 in Transformation of Multiple Tissues. Molecular and Cellular Biology, 2000, 20, 4462-4473.	2.3	92
27	The role of c-myc in cellular growth control. Oncogene, 1999, 18, 2988-2996.	5.9	345
28	Coordination of cell growth with cell division. Current Opinion in Genetics and Development, 1999, 9, 76-80.	3.3	126
29	Novel Regulatory Factors Interacting with the Promoter of the Gene Encoding the mRNA Cap Binding Protein (eIF4E) and Their Function in Growth Regulation. Molecular and Cellular Biology, 1998, 18, 5621-5633.	2.3	26
30	Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Letters, 1997, 113, 123-130.	7.2	61
31	Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. Somatic Cell and Molecular Genetics, 1997, 23, 221-223.	0.7	5
32	Happenstance, circumstance or enemy action: Cyclin D1 in breast, eye and brain. BioEssays, 1996, 18, 6-8.	2.5	3
33	MYC family ties. Nature Genetics, 1996, 14, 8-10.	21.4	14
34	Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels. Journal of Biological Chemistry, 1995, 270, 21176-21180.	3.4	226
35	Hepatocyte growth factor in transgenic mice: Effects on hepatocyte growth, liver regeneration and gene expression. Hepatology, 1994, 19, 962-972.	7.3	156
36	Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 1994, 369, 669-671.	27.8	929

#	Article	IF	Citations
37	Hepatocyte growth factor in transgenic mice: Effects on hepatocyte growth, liver regeneration and gene expression. Hepatology, 1994, 19, 962-972.	7.3	19
38	Zidovudine-Associated Embryonic Toxicity in Mice. Journal of Infectious Diseases, 1991, 163, 1212-1218.	4.0	62